FDA Quality Profiling: Agency Hopes to Channel Corporate Attention (And Money) To Quality Systems

FDA’s drug compliance leadership sees new risk assessment authority for setting inspection schedules from FDASIA as an appealing foundation for collecting and preparing profiles of drug manufacturers. Just don’t call them “report cards.”